Flexible Assay Technology for Studying Diverse Applications

Most Eurofins DiscoverX® cell lines and cell-based assays are based on the Enzyme Fragment Complementation Technology (EFC) technology. This patented technology provides drug discovery and development researchers the means to interrogate biomolecular reactions for advancing therapeutic drug screening and development programs. EFC is a homogeneous detection assay system that enables you to measure and rank ligand potencies, discover the MOA, perform binding and functional screens, identify novel compounds, and much more.

EFC has been used as a robust and reliable assay technology for decades in >1M programs including >250 stability and commercial release programs. Eurofins DiscoverX has developed numerous assay formats to interrogate the desired MOA of therapeutics such as PathHunter®, HitHunter®, KILR®, InCELL, and SPRINTer™. These assay formats are used from discovery through development into lot release testing and stability studies of many small molecule and biological therapeutics on the market today and within clinical trials.

Directly Measure Relevant Target Biology with Ease

  • Homogeneous Format — Add-and-read assay format without the need for washing, centrifugation, or filtration
  • Robust — Enzymatically-amplified assays with large signal-to-background ratios and high precision with Z’ factors > 0.7 and lot-to-lot reproducibility
  • Qualified and Validated — Extensively optimized for hundreds of targets used for screening billions of data points, and cited in thousands of peer-reviewed publications
  • Scalable — Easily scalable and HTS-friendly from 96- to 3456-well microplate format

Highlights of EFC-Based Assays

HomogeneousSensitive DetectionRobustLuminescence ReadoutEasy to Transfer
  • Simple add-and-read assay format
  • No media change, shaking, or filtration
  • Enzymatically-amplified assay
  • High precision & accuracy
  • Large dynamic range
  • High assay reproducibility
  • Easily quantified luminescence readout
  • Compatible with most readers
  • Assay protocol is similar across the platform
  • Detailed user manuals

EFC Technology Principle

EFC Technology Principle

EFC is based on two recombinant β-galactosidase (β-gal) enzyme fragments that act as an enzyme acceptor (EA) and an enzyme donor (ED). Separately, the fragments are inactive, but when combined, they form an active β-gal enzyme that hydrolyzes its substrate to produce a chemiluminescence signal.

Assay Formats for Your Modality and Stage of Development

Assay Platforms for Your Modality and Stage of Development